argenx reports positive phase 3 data for autoimmune myositis drug
Covered in this story
Analyst targets on argenx
- Baird: $876 → $861 by Oct 2027 · Neutral via Investing.com
- Jefferies: $876 → $1.2k by Oct 2027 · Buy via Investing.com
- Stifel: $876 → $1.2k by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ARGX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on argenx →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.